ABVX vs. GLPG, ARQT, INDV, AKRO, DYN, IMCR, EVO, TVTX, VIR, and GPCR
Should you be buying ABIVAX Société Anonyme stock or one of its competitors? The main competitors of ABIVAX Société Anonyme include Galapagos (GLPG), Arcutis Biotherapeutics (ARQT), Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Immunocore (IMCR), Evotec (EVO), Travere Therapeutics (TVTX), Vir Biotechnology (VIR), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.
ABIVAX Société Anonyme vs.
Galapagos (NASDAQ:GLPG) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
Galapagos received 457 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 81.82% of users gave ABIVAX Société Anonyme an outperform vote while only 64.01% of users gave Galapagos an outperform vote.
Galapagos has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, ABIVAX Société Anonyme has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
In the previous week, Galapagos and Galapagos both had 2 articles in the media. ABIVAX Société Anonyme's average media sentiment score of 0.48 beat Galapagos' score of 0.26 indicating that ABIVAX Société Anonyme is being referred to more favorably in the news media.
32.5% of Galapagos shares are held by institutional investors. Comparatively, 47.9% of ABIVAX Société Anonyme shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Galapagos presently has a consensus price target of $30.75, indicating a potential upside of 29.42%. ABIVAX Société Anonyme has a consensus price target of $38.67, indicating a potential upside of 527.71%. Given ABIVAX Société Anonyme's stronger consensus rating and higher possible upside, analysts plainly believe ABIVAX Société Anonyme is more favorable than Galapagos.
Galapagos has higher revenue and earnings than ABIVAX Société Anonyme.
Summary
ABIVAX Société Anonyme beats Galapagos on 8 of the 12 factors compared between the two stocks.
Get ABIVAX Société Anonyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABIVAX Société Anonyme Competitors List
Related Companies and Tools
This page (NASDAQ:ABVX) was last updated on 1/20/2025 by MarketBeat.com Staff
Free ABVX Stock Alerts